ClinicalTrials.gg
RecruitingNCT06171568ECOGUpdated May 31, 2024

Lariboisière Cognitive Assessment: Evaluation of the 1-year Outcomes

An observational study in Brain Injuries, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Brain Injuries by Assistance Publique - Hôpitaux de Paris — 4 open to participants now, 4 under way, none of them phase 3. Brain Injuries · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
Observational
7 of 11
4 open now
Registered
9th of 11
by date

Among the 11 studies in Brain Injuries by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 7 observational ones, and was the 9th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

4 of the 11 studies in Brain Injuries by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Injuries by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Cognitive sequelae are common following acquired brain injuries. However, their detection can be challenging, particularly in acute care units such as neurosurgery. Specific screening in acute phase is critical for early detection and proper orientation. The Lariboisière cognitive assessment (Cog-First) is a brief cognitive evaluation conducted on a touch-screen tablet for patients with acquired brain injuries in the acute phase, which is integrated into routine care in Lariboisière.

The objective of this project is to evaluate the one-year cognitive and functional outcomes of patients who have undergone hospitalization in neuro-surgery. The primary aim is to assess whether the systematic pre-discharge assessment (Cog-First) performed as part of routine care can predict a poor functional prognosis and help identify at-risk patients earlier and more effectively.

Read the detailed description

Traumatic brain injuries (TBI) are responsible for about 262 hospitalizations per 100,000 inhabitants in Europe each year. After a traumatic brain injury, 704 out of 100,000 individuals experience long-term consequences, including motor and/or balance disorders, fatigue, chronic pain, psychological disorders, and cognitive impairments such as memory problems, difficulties in comprehension, attentional deficits, and impairment of working memory. Without adequate rehabilitation, cognitive impairments can persist for several years, leading to significant socio-professional consequences such as job loss and social isolation, as well as medical and economic consequences.

The Paris TBI study showed that upon discharge from acute care services, only 45% of patients who had suffered severe traumatic brain injuries were referred to specialized rehabilitation facilities, while 30% returned directly home. Additionally, there is a lack of cognitive assessment in acute care services. For instance, in services that treat stroke patients, only 61% of patients will meet with a rehabilitation professional before their discharge. Short cognitive screening batteries typically used in the acute phase to guide patients' discharge from the hospital include the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination (MMSE). However, these scores are not very specific or sensitive, are examiner-dependent, and require trained personnel. Currently, there are few validated digital cognitive assessment batteries available for acute-phase evaluation and routine use in traumatic brain injury patients. Furthermore, evaluating cognitive impairments early after a traumatic brain injury can be challenging due to various confounding factors (e.g., fatigue, stressful hospitalization context) and organizational factors. Nevertheless, early assessment of cognitive impairments remains essential in order to appropriately refer patients, if necessary, to specialized rehabilitation facilities.

To address the need for better early detection of cognitive impairment following brain injuries, the investigators have developed the Cognitive Evaluation of Lariboisière (also known as Cog-First), a screening battery for cognitive impairments on a tablet device that can be quickly and independently completed by patients. Cog-First is now integrated into routine care in Lariboisière as a systematic pre-discharge assessment for patients discharged home without rehabilitation plan.

The main goal of this project is to identify patients who are at risk of experiencing cognitive impairments that could significantly impact their long-term functional prognosis. The investigators will evaluate whether the initial results obtained through the systematic evaluation using Cog-First at the time of discharge can accurately predict the functional and cognitive outcomes at one year. This could enable us to identify at-risk patients before discharge from acute care and refer them to specialized rehabilitation units earlier, leading to improved future outcomes for these individuals.

During the 1-year follow-up consultation after hospital discharge, eligible patients will be offered the opportunity to participate in the study. If they consent, their functional and cognitive abilities will be assessed using a set of tests and questionnaires. The assessments will include the modified Rankin score, IADL questionnaire, MoCA, Bref, Rivermead questionnaire, SF-36 questionnaire, CIQ-R questionnaire, and PCL-5 questionnaire.

03

Conditions studied

  • Brain Injuries

Keywords

  • Brain injuries
  • Prognosis
  • Cognitive impairment
  • Cognition
  • Executive Function
  • Neuropsychological tests
  • Neuro-rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized at Lariboisière hospital in neurosurgery unit between February 2023 and February 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age
  • Patient hospitalized in neurosurgery unit at Lariboisière hospital between February 2023 and February 2024
  • Patient discharged home
  • Patient affiliated to the social security system
  • Patient having expressed no opposition

Exclusion criteria

Exclusion Criteria:

  • Patient transferred to a rehabilitation facility following hospitalization in neurosurgery
  • History of neurological or psychiatric illness
  • Severe uncorrected visual impairment and/or aphasia
  • Non-French-speaking patients
  • Patients receiving State Medical Aid (AME)
  • Patients under guardianship/curatorship
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • OtherTests and questionnaires

    1 year after discharge from neurosurgery department, included patients will answer to the: * Modified Rankin Scale; * Instrumental Activities of Daily Living (IADL) questionnaire; * Montreal Cognitive Assessment (MoCA); * Frontal assessment battery (BREF); * Rivermead questionnaire; * Short Form (36) Health Survey (SF-36) * Community Integration Questionnaire - Revised (CIQ-R) * Posttraumatic stress disorder CheckList (PCL-5)

06

What researchers measure

Primary outcomes

  1. Evaluation of the functional outcome at 1 year of patients who were hospitalized in the Lariboisière neurosurgery department compared with the initial systematic cognitive assessment (Cog-First)

    The Modified Rankin Scale (MRS) will be used during the systematic follow-up consultation. The MRS is a score allowing functional independence level notation from 0 (no symptoms or incapacity) to 5 (severe disability).

    Time frame: 1 year

Secondary outcomes

  1. Assessment of the independence of patients in their daily life.

    The Instrumental Activities of Daily Living (IADL) questionnaire will be submitted to patients. The IADL questionnaire gives a score going from 0 to 8. Higher score mean a better outcome.

    Time frame: 1 year

  2. Mesure of different cognitive functions of patients (language, memory, visio-spatial functions, attention, concentration, orientation in time and space).

    Montreal Cognitive Assessment (MoCA) will be the used tool to answer this outcome. The MoCA gives a score going from 0 to 30. Higher score mean a better outcome.

    Time frame: 1 year

  3. Assess various cognitive functions in patients, including language, memory and visio-spatial abilities

    The "Batterie Rapide d'Efficience Frontale" (BREF) test is a frontal assessment battery which will be used to question patients. The BREF test gives a score going from 0 to 18. Higher score mean a better outcome.

    Time frame: 1 year

  4. Rivermead questionnaire

    Assessment of the post-concussion syndrome. The Rivermead questionnaire gives a score going from 0 to 52. Higher score mean a worse outcome.

    Time frame: 1 year after discharge from Neurosurgery department of Lariboisière

  5. Short Form (36) Health Survey (SF-36)

    Assessment of quality of life. The SF-36 gives a score going from 0 to 100. Higher score mean a better outcome.

    Time frame: 1 year after discharge from Neurosurgery department of Lariboisière

  6. Community Integration Questionnaire - Revised (CIQ-R)

    Assessment of socio-professional reintegration. The CIQ-R gives a score going from 0 to 35. Higher score mean a better outcome.

    Time frame: 1 year after discharge from Neurosurgery department of Lariboisière

  7. Posttraumatic stress disorder CheckList (PCL-5)

    Assessment of post-traumatic stress. The PCL-5 gives a score going from 0 to 80. Higher score mean a worse outcome.

    Time frame: 1 year after discharge from Neurosurgery department of Lariboisière

07

Study locations

1 of 1 sites recruiting
  • Neurosurgery - Lariboisière hospital
    Paris, Ile-de-France 75010, France
    Recruiting
08

References and documents

Publications

  • Peeters W, van den Brande R, Polinder S, Brazinova A, Steyerberg EW, Lingsma HF, Maas AI. Epidemiology of traumatic brain injury in Europe. Acta Neurochir (Wien). 2015 Oct;157(10):1683-96. doi: 10.1007/s00701-015-2512-7. Epub 2015 Aug 14. PubMed 26269030 ↗
  • Jourdan C, Azouvi P, Genet F, Selly N, Josseran L, Schnitzler A. Disability and Health Consequences of Traumatic Brain Injury: National Prevalence. Am J Phys Med Rehabil. 2018 May;97(5):323-331. doi: 10.1097/PHM.0000000000000848. PubMed 29016402 ↗
  • Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil. 2006 Sep-Oct;21(5):375-8. doi: 10.1097/00001199-200609000-00001. PubMed 16983222 ↗
  • Stocchetti N, Zanier ER. Chronic impact of traumatic brain injury on outcome and quality of life: a narrative review. Crit Care. 2016 Jun 21;20(1):148. doi: 10.1186/s13054-016-1318-1. PubMed 27323708 ↗
  • Jourdan C, Bayen E, Bosserelle V, Azerad S, Genet F, Fermanian C, Aegerter P, Pradat-Diehl P, Weiss JJ, Azouvi P; Members of the Steering Committee of the PariS-TBI Study. Referral to rehabilitation after severe traumatic brain injury: results from the PariS-TBI Study. Neurorehabil Neural Repair. 2013 Jan;27(1):35-44. doi: 10.1177/1545968312440744. Epub 2012 Mar 28. PubMed 22460612 ↗
  • Schnitzler A, Erbault M, Solomiac A, Sainte Croix D, Fouchard A, May-Michelangeli L, Grenier C. Early rehabilitation after stroke: Strong recommendations but no achievement in the French Acute Healthcare Facilities. Ann Phys Rehabil Med. 2019 Jan;62(1):58-59. doi: 10.1016/j.rehab.2018.07.001. Epub 2018 Jul 19. No abstract available. PubMed 30031892 ↗
  • Rodrigues JC, Becker N, Beckenkamp CL, Mina CS, de Salles JF, Bandeira DR. Psychometric properties of cognitive screening for patients with cerebrovascular diseases A systematic review. Dement Neuropsychol. 2019 Jan-Mar;13(1):31-43. doi: 10.1590/1980-57642018dn13-010004. PubMed 31073378 ↗
  • de Guise E, Leblanc J, Champoux MC, Couturier C, Alturki AY, Lamoureux J, Desjardins M, Marcoux J, Maleki M, Feyz M. The mini-mental state examination and the Montreal Cognitive Assessment after traumatic brain injury: an early predictive study. Brain Inj. 2013;27(12):1428-34. doi: 10.3109/02699052.2013.835867. Epub 2013 Oct 8. PubMed 24102622 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

Of 144 non-industry observational studies under Brain Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 149 studies reached it within 31 months; a quarter within 16 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Mar 22, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06171568
Collaborators
SBT Human(s) Matter
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Mar 22, 2024
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
May 31, 2024

Study contacts

Camille Heslot, MD
Contact
camille.heslot@aphp.fr
01.49.95.81.69 ext. +33
Alexis Schnitzler, MD, PhD
Contact
alexis.schnitzler@aphp.fr
01.40.05.49.58 ext. +33
Emmanuel Mandonnet, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris
Alexis Schnitzler, MD, PhD
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion